chevron_leftBack
As of 13 June 2026, Replimune Group, Inc. has a market cap of $196.52M USD, ranking #21175 globally and #3452 in the United States.
It ranks #1893 in the Healthcare sector, and #364 in the Biotechnology industry.
Key Stats
Market Cap
$196.52MUSD
Enterprise Value
$3.73MUSD
EBITDA (TTM)
-$318.88MUSD
Net Income (TTM)
-$314.85MUSD
PB Ratio
1.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Sushil Patel
open_in_new
Employees
479
Founded
2015
IPO
20 Jul 2018
Website
replimune.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -7.4% | 30% | -67% | -67% | -77% | -74% |
News
Loading...
REPL Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
REPL
Replimune Group Inc
ISIN: US76029N1063
Shares Out.:
Shares Outstanding:
82.573M1
Shares Float:
76.243M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
2.38 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Replimune Group, Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
93K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
81K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
14K%
|
-
|
|
NYSE: IQV
|
$26.3B
13K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
13K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
9K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
24K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
23K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
21K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
21K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
14K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
13K%
|
-
|
chevron_leftBack